(0.27%) 5 105.25 points
(0.60%) 38 612 points
(0.60%) 17 756 points
(0.34%) $79.22
(-0.79%) $2.02
(0.30%) $2 316.60
(0.60%) $26.99
(0.51%) $967.50
(-0.08%) $0.931
(-0.15%) $10.97
(-0.17%) $0.797
(0.82%) $91.88
Live Chart Being Loaded With Signals
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes...
Stats | |
---|---|
Šios dienos apimtis | 169 171 |
Vidutinė apimtis | 328 385 |
Rinkos kapitalizacija | 80.25M |
EPS | $0 ( 2024-02-22 ) |
Kita pelno data | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.13 |
ATR14 | $0.00200 (1.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-25 | Pershing Edward | Buy | 37 752 | Series D-1 Convertible Preferred Stock |
2024-04-25 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-19 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-11 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 17 761 544 | Sell: 0 |
Provectus Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Provectus Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $557 710 |
Bruto pelnas: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2023 |
Pajamos: | $557 710 |
Bruto pelnas: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2022 |
Pajamos: | $989 042 |
Bruto pelnas: | $925 264 (93.55 %) |
EPS: | $-0.00850 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.0100 |
Financial Reports:
No articles found.
Provectus
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.